The company behind Marťánci vitamins pocketed CZK 242m of operating profit in 2025

A quiet year on the shelf, a loud one in the accounts

If you have ever bought chewable vitamins for a child in a Czech pharmacy, or a box of joint supplements for a parent, there is a fair chance the pack came from Walmark. The company, based in Třinec and part of the pharmaceutical group STADA, makes and sells dietary supplements. It is an a.s., a Czech joint-stock company. The figures here are its own standalone accounts under Czech accounting rules, in CZK, for calendar years.

On the shelf, 2025 looked ordinary. Revenue rose 4.9%, from CZK 1.7bn to CZK 1.8bn. That is roughly the pace at which prices and a few new product lines can lift sales without anyone noticing.

The income statement noticed. Operating profit, what is left after running the business but before interest and tax, went from CZK 83.2m to CZK 242m, up 190.5%. Profit grew about 38.8× as fast as revenue. The operating margin, the share of each koruna of sales kept as operating profit, widened from 5.0% to 13.8%.

The detail that changes the picture: operating profit rose by CZK 158m, while revenue rose by only CZK 81.9m. Profit gained more koruna than sales did. Put simply, Walmark spent less to run itself in 2025 than in 2024, while selling more.

Cheaper to run, not just fuller

The usual explanation for profit outrunning sales is the fixed-cost effect. A supplement maker carries a heavy base of costs that barely move with volume: the factory, the quality laboratories, the regulatory work for each market, the sales teams and the management. Once revenue covers that base, most of each extra koruna falls to profit. That logic explains why a small rise in sales can do a lot.

It cannot explain all of this. Fixed costs that stay flat would let profit rise by at most the amount revenue rose. Walmark's profit rose by more, so some costs must have fallen in absolute terms. Depreciation, the cost of wearing out machines and buildings, did not move: CZK 57.9m in 2025 against CZK 57.7m a year earlier. The saving sat elsewhere, in the cash costs of running the business. EBITDA, operating profit with depreciation added back, rose 112.7% to CZK 300m.

The accounts do not break the saving down by type of cost. In a supplement business the likely candidates are cheaper ingredients and packaging, a lighter marketing budget after a heavy campaign year, or a different price for goods and services traded with the rest of the STADA group. The split of material, marketing and staff costs would settle it. Each cause lasts a different length of time: a cheaper vitamin premix can reverse with the next contract, a smaller advertising spend can cost sales later, and a change in group pricing stays as long as the group wants it to.

Management's stated aim is for Walmark to become a centre of excellence within STADA for producing dietary supplements. A plant that becomes the group's specialist manufacturer often trims its own overheads, and that would fit the pattern. I would not treat it as proven.

Where the extra profit went

Most of the money appears to have stayed in the company. Net profit, after interest and tax, rose 135.9% to CZK 142m, and the net margin reached 8.1% against 3.6% in 2024. Equity grew by CZK 140m to CZK 348m, close to the year's net profit, which suggests the earnings stayed in the business. The equity ratio, the share of assets financed by the owner rather than by creditors, rose from 14.9% to 25.8%, on total assets of about CZK 1.4bn.

Cash went the other way. It fell CZK 30.8m to CZK 79.6m. A rising profit with a falling cash balance is not alarming in itself, since money can go into stock, receivables or repayments, but it means the better year has not yet shown up as a bigger cushion in the bank. PricewaterhouseCoopers Audit gave the 2025 statements an unqualified opinion.

Against a benchmark of 8 comparable Czech companies, Walmark's operating margin of 13.8% sits 5.8 pp above their median of 8.0%. Its net margin is 4.0 pp above the benchmark median of 4.1%. A year earlier, its operating margin of 5.0% would have sat below that median. The company did not drift into the top half; it jumped there in a single year.

The lever points both ways

For shoppers, nothing here should change the price of a box of vitamins tomorrow. For the market, it shows how much of a branded supplement business is decided away from the pharmacy counter, in the cost of ingredients, the advertising plan and the terms set inside a larger group.

The same structure that lifted 2025 works in reverse. A company with a heavy fixed base loses profit quickly when sales slip. Walmark has already named one risk: after the balance sheet date, sanctions against Russian entities led to limited or delayed deliveries to some eastern markets. Those are exactly the kind of sales whose loss would come straight out of profit, because the factory and the teams cost the same either way.

For anyone running a business with a large fixed base, the check is simple. Split your costs into those that move with sales and those that do not, then work out how far revenue could fall before operating profit reaches zero. If last year's profit came partly from cheaper costs, as Walmark's did, run the check again with the old costs.

I would watch two lines in the 2026 accounts: sales to the eastern markets and the cost of running the business. Walmark made 2025 look easy, and a profit that grew faster than sales can shrink faster than sales too.